YARW
Yarrow Bioscience Inc
Price Chart
Latest Quote
$20.12
+0.12 (+0.60%)
Current Price
| Previous Close | $20.00 |
| Open | $19.95 |
| Day High | $20.23 |
| Day Low | $19.18 |
| Volume | 231,112 |
Stock Information
| Shares Outstanding | 9.30M |
| Cash Equivalents | $18.67M |
| Net Income | $-283.98M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $187.20M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $142.50M |
| Income | $-283.98M |
| Book/sh | $-26.06 |
| Cash/sh | $2.01 |
| Employees | 7 |
Financial Ratios
| Quick Ratio | 1.40 |
| Current Ratio | 1.40 |
Returns & Margins
Ownership
| Insider Ownership | 2.02% |
| Institutional Ownership | 38.02% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -12.19 |
| P/B | -0.77 |
Analyst Data
| Recommendation | none |
| Target Price | $57.00 |
Technical Indicators
| SMA20 | $20.04 |
| SMA50 | $26.80 |
| SMA200 | $21.72 |
| RSI | 57.18 |
| ATR | 1.4321 |
| Shares Float | 1.75M |
| Short Ratio | 1.15 |
| Volatility | 2.08 |
| Rel Volume | 1.93 |
Performance History
| Week | -0.45% |
| Month | -16.17% |
| Quarter | -33.92% |
| 6 Months | +11.39% |
| YTD | +22.91% |
| Year | +91.12% |
| 3 Years | -72.89% |
| 5 Years | -96.43% |
| 10 Years | -99.97% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $20.12 | 231,112 |
| 2026-10-26 | $20.00 | 162,200 |
| 2026-10-23 | $19.27 | 146,400 |
| 2026-10-22 | $19.60 | 143,800 |
| 2026-10-21 | $20.17 | 73,500 |
| 2026-10-20 | $20.21 | 105,900 |
| 2026-10-19 | $19.98 | 215,600 |
| 2026-10-16 | $18.31 | 60,900 |
| 2026-10-15 | $20.00 | 183,600 |
| 2026-10-14 | $18.90 | 105,600 |
| 2026-10-13 | $18.60 | 99,800 |
| 2026-10-12 | $19.82 | 88,600 |
| 2026-10-09 | $19.71 | 162,200 |
| 2026-10-08 | $19.87 | 94,800 |
| 2026-10-07 | $18.77 | 140,500 |
| 2026-10-06 | $18.73 | 69,200 |
| 2026-10-05 | $20.30 | 102,500 |
| 2026-10-02 | $22.27 | 66,100 |
| 2026-10-01 | $23.60 | 35,400 |
| 2026-09-30 | $22.52 | 105,700 |
| 2026-09-29 | $24.19 | 100,600 |
| 2026-09-28 | $24.00 | 107,700 |
About Yarrow Bioscience Inc
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
đ° Latest News
No news articles available at the moment. Check back later for updates on YARW.
Period:
Loading...
Balance Sheet (Annual)
| Metric | 2025-12-31 |
|---|---|
| Assets | |
| Net Tangible Assets | $28,860,000 |
| Total Assets | $100,407,000 |
| Total Non Current Assets | $407,000 |
| Non Current Deferred Assets | $407,000 |
| Current Assets | $100,000,000 |
| Other Current Assets | $6,000 |
| Receivables | $0 |
| Cash Cash Equivalents And Short Term Investments | $99,994,000 |
| Cash And Cash Equivalents | $99,994,000 |
| Cash Financial | $99,994,000 |
| Liabilities | |
| Total Liabilities Net Minority Interest | $71,547,000 |
| Total Non Current Liabilities Net Minority Interest | $0 |
| Current Liabilities | $71,547,000 |
| Payables And Accrued Expenses | $71,547,000 |
| Payables | $1,534,000 |
| Accounts Payable | $1,534,000 |
| Equity | |
| Common Stock Equity | $-70,990,000 |
| Preferred Stock Equity | $99,850,000 |
| Total Equity Gross Minority Interest | $28,860,000 |
| Stockholders Equity | $28,860,000 |
| Retained Earnings | $-70,994,000 |
| Other | |
| Ordinary Shares Number | $2,803,078 |
| Share Issued | $2,803,078 |
| Tangible Book Value | $-70,990,000 |
| Invested Capital | $-70,990,000 |
| Working Capital | $28,453,000 |
| Total Capitalization | $28,860,000 |
| Additional Paid In Capital | $4,000 |
| Capital Stock | $99,850,000 |
| Common Stock | $0 |
| Preferred Stock | $99,850,000 |
| Current Accrued Expenses | $70,013,000 |
Fetched: 2026-10-17